MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 120209 | Name: Ruxolitinib phosphate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ruxolitinib, also known as INC424 and INCB18424 or INCB018424, is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Chemical Structure

Ruxolitinib phosphate
Ruxolitinib phosphate
CAS#1092939-17-7 (phosphate)

Theoretical Analysis

MedKoo Cat#: 120209

Name: Ruxolitinib phosphate

CAS#: 1092939-17-7 (phosphate)

Chemical Formula: C17H21N6O4P

Exact Mass: 404.1362

Molecular Weight: 404.37

Elemental Analysis:

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 150.00 Ready to ship
50mg USD 200.00 Ready to ship
100mg USD 300.00 Ready to ship
200mg USD 500.00 Ready to ship
500mg USD 750.00 Ready to ship
1g USD 1,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
941678-49-5 (free base) 1092939-17-7 (phosphate)
Synonym
INCB018424; INCB 018424; INCB-018424; INC424; INC-424; INC424; INCB18424; INCB 18424; INCB-18424; trade name: Jakafi and Jakavi
IUPAC/Chemical Name
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate
InChi Key
JFMWPOCYMYGEDM-XFULWGLBSA-N
InChi Code
InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
SMILES Code
N#CC[C@@H](N1N=CC(C2=C3C(NC=C3)=NC=N2)=C1)C4CCCC4.O=P(O)(O)O
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO and ethanol
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
 
Biological target:
Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively.
In vitro activity:
In this report, the preclinical characterization of INCB018424, a potent, selective, and orally bioavailable inhibitor of JAK1 and JAK2 was described. The results shown in Table 1 demonstrated the potent in vitro activity of INCB018424 on wild-type JAK1 and JAK2. Although there is no biochemical basis for differential activity of ATP-competitive kinase inhibitors on the mutant JAK2V617F, the effect of INCB018424 on cells driven by JAK2V617F is not known. To better understand the consequences of JAK1/2 inhibition in cells expressing mutated JAK2, Ba/F3-EpoR-JAK2V617F cells were treated with INCB018424 and a viable cell number was assessed after 48 hours. A dose-dependent reduction in viability was observed with an IC50 of 126nM (Figure 1D square). Growth of HEL cells was also affected by INCB018424 with a 50% effective concentration (EC50) of 186nM. Unlike the BaF/3 cells, HEL cell proliferation was not completely inhibited by INCB018424 (Figure 1B), even though pSTAT3 and pSTAT5 were completely absent at concentrations more than 100nM (Figure 1D triangle) suggesting that the proliferation in these cells is not entirely JAK2V617F dependent. Importantly, the sensitivity of these cell lines to the effects of INCB018424 was in stark contrast to the lack of effect on TF-1 or BaF/3 cells transformed with the BCR-ABL oncoprotein. In these cells, no significant effect on viability was observed, consistent with the selective nature of INCB018424 (Figure 1D, diamond and open square). Likewise, 2 cell lines expressing activating mutations in c-KIT (HMC1.1 and HMC1.2) were also resistant (data not shown). INCB018424 also had no effect on BCRABL signaling, as demonstrated by an inability to reduce ABL-mediated pSTAT5, in contrast to imatinib. It was demonstrated that, at nanomolar concentrations, INCB018424 inhibits JAK2V617F, STAT5, and ERK1/2 phosphorylation resulting in reduced cellular proliferation and the induction of apoptosis by JAK2V617F+ Ba/F3 cells. Blood. 2010 Apr 15; 115(15): 3109–3117. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953826/
In vivo activity:
Mice receiving 75 mg/kg ruxolitinib or vehicle 6 hours prior to and 6 hours after injection of OVA/CpG were analyzed for expression of activation markers on CD11c+CD8+ splenic DCs. Indeed, lower expression levels of CD40, CD80, CD86 as well as MHC I and II molecules were detected in ruxolitinib-challenged animals (Figure 4A). Next, ruxolitinib or vehicle was fed to mice 6 hours prior to as well as 6 hours and 18 hours after priming with OVA/CpG and adoptive transfer of CFSE-labeled OT-I cells. OVA is usually taken up by DCs in vivo and then cross-presented on MHC class I molecules. Analysis of transferred CFSE-labeled OT-I T cells revealed reduced proliferation (Figure 4B-C), CD25 expression (Figure 4D-E), and IFN-γ production (Figure 4F-G) in mice pretreated with ruxolitinib. The effects of ruxolitinib on the induction of cytotoxic activity of CD8+ T cells in a non–TCR-transgenic setting were evaluated. To this end, the in vivo cytotoxic T-cell response against OVA in C57/BL6N mice primed with OVA/CpG either exposed to ruxolitinib or vehicle was quantified. Using this assay, it has been shown that ruxolitinib markedly reduces OVA-specific cytotoxic activity (Figure 4H). Blood. 2013 Aug 15;122(7):1192-202. https://pubmed.ncbi.nlm.nih.gov/23770777/
Solvent mg/mL mM
Solubility
DMSO 50.8 125.66
Ethanol 6.5 16.07
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 404.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. PMID: 20130243; PMCID: PMC3953826. 2. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14. PMID: 23770777.
In vitro protocol:
1. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. PMID: 20130243; PMCID: PMC3953826. 2. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14. PMID: 23770777.
In vivo protocol:
1. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. PMID: 20130243; PMCID: PMC3953826. 2. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14. PMID: 23770777.
: Boldrini V, Vannucchi AM, Guglielmelli P. A safety evaluation of ruxolitinib for the treatment of polycythemia vera. Expert Opin Drug Saf. 2023 Dec 29:1-7. doi: 10.1080/14740338.2023.2299391. Epub ahead of print. PMID: 38156903. 2: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Ruxolitinib. 2023 Dec 15. PMID: 29999923. 3: Adesola AA, Cozma MA, Chen YF, Srichawla BS, Găman MA. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. World J Hepatol. 2023 Nov 27;15(11):1188-1195. doi: 10.4254/wjh.v15.i11.1188. PMID: 38075009; PMCID: PMC10698348. 4: Yunianto I, Currie M, Chitcholtan K, Sykes P. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer. J Obstet Gynaecol Res. 2023 Nov;49(11):2563-2574. doi: 10.1111/jog.15761. Epub 2023 Aug 10. PMID: 37565583. 5: Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, Quaglino P, Zalaudek I, Marzano AV, Ribero S, Alberti-Violetti S. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2222-2230. doi: 10.1111/jdv.19162. Epub 2023 May 15. PMID: 37147856. 6: Yan WL, Zhao FY, Gu ME, Liu N, Guo XP, Xu XJ. Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature. Paediatr Drugs. 2023 Sep;25(5):577-584. doi: 10.1007/s40272-023-00577-8. Epub 2023 Jun 7. PMID: 37284944. 7: Al Sharie AH, Abu Mousa BM, Alomari AO. Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand? Clin Hematol Int. 2023 Aug 28;5(4):1-4. doi: 10.46989/001c.87501. PMID: 37752987; PMCID: PMC10515879. 8: Hwang JR, Driscoll MS. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo. Ann Pharmacother. 2023 Aug;57(8):948-955. doi: 10.1177/10600280221143748. Epub 2022 Dec 23. PMID: 36564903. 9: Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023 Jul 27;16(1):82. doi: 10.1186/s13045-023-01471-z. PMID: 37501130; PMCID: PMC10373260. 10: Algeri M, Becilli M, Locatelli F. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease. Expert Rev Clin Immunol. 2023 Jul-Dec;19(11):1299-1313. doi: 10.1080/1744666X.2023.2249230. Epub 2023 Aug 22. PMID: 37606511. 11: Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 Jun;64(6):1063-1081. doi: 10.1080/10428194.2023.2196593. Epub 2023 Apr 20. PMID: 37081809. 12: Mancuso-Stewart E, DiRuggiero M, DiRuggiero D, Zirwas M. New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 1: Ruxolitinib. Skinmed. 2023 May 9;21(2):93-98. PMID: 37158346. 13: Kashetsky N, Turchin I. Utilization of Topical Ruxolitinib in Dermatology: A Review. Skin Therapy Lett. 2023 May;28(3):8-13. PMID: 37339609. 14: Krajewski PK, Szepietowski JC. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis. Expert Rev Clin Immunol. 2023 Apr;19(4):349-356. doi: 10.1080/1744666X.2023.2161511. Epub 2022 Dec 26. PMID: 36542765. 15: Mohney LA, Singh R, Feldman SR. Review of Ruxolitinib in the Treatment of Atopic Dermatitis. Ann Pharmacother. 2023 Feb;57(2):207-216. doi: 10.1177/10600280221103282. Epub 2022 Jun 8. PMID: 35674400. 16: Hoy SM. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis. Am J Clin Dermatol. 2023 Jan;24(1):143-151. doi: 10.1007/s40257-022-00748-2. Epub 2022 Dec 20. Erratum in: Am J Clin Dermatol. 2023 May;24(3):495. PMID: 36538235; PMCID: PMC10036407. 17: Li GM, Jin YB, Gan YZ, Chen C, Jia Y, Li C. [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review]. Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Dec 18;54(6):1208-1213. Chinese. doi: 10.19723/j.issn.1671-167X.2022.06.025. PMID: 36533357; PMCID: PMC9761834. 18: Devos T, Selleslag D, Granacher N, Havelange V, Benghiat FS. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology. 2022 Dec;27(1):23-31. doi: 10.1080/16078454.2021.2009645. PMID: 34957926. 19: Sadeghi S, Goodarzi A. Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective. Dermatol Pract Concept. 2022 Oct 1;12(4):e2022178. doi: 10.5826/dpc.1204a178. PMID: 36534552; PMCID: PMC9681403. 20: Owji S, Caldas SA, Ungar B. Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib. J Asthma Allergy. 2022 Oct 25;15:1527-1537. doi: 10.2147/JAA.S342051. PMID: 36316998; PMCID: PMC9617518.